Treatment of Hodgkin's disease in children with or without radiotherapy

Authors

  • Henk Behrendt MD,

    Corresponding author
    1. Werkgroep Kindertumoren, Emma Kinderziekenhuis and Antoni van Leeuwenhoekhuis, the Netherlands Cancer Institute, 1018 HJ Amsterdam, The Netherlands
    • Emma Kinderziekenhuis, Spinozastraat 51, 1018 HJ Amsterdam, The Netherlands
    Search for more papers by this author
  • Bart N. F. M. van Bunningen MD,

    1. Werkgroep Kindertumoren, Emma Kinderziekenhuis and Antoni van Leeuwenhoekhuis, the Netherlands Cancer Institute, 1018 HJ Amsterdam, The Netherlands
    Search for more papers by this author
  • Eleonore F. van Leeuwen MD

    1. Werkgroep Kindertumoren, Emma Kinderziekenhuis and Antoni van Leeuwenhoekhuis, the Netherlands Cancer Institute, 1018 HJ Amsterdam, The Netherlands
    Search for more papers by this author

Abstract

From 1975 until 1984 37 children with newly diagnosed Hodgkin's disease were treated with six mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) courses with or without involved field radiotherapy (25 Gy) independent of the stage of their disease. Patients with small lymph node tumors (<4 cm) received only six MOPP-courses. Patients with large lymph node tumors (>4 cm) received involved field radiotherapy, 25 Gy to the large tumor masses, between the third and fourth MOPP-course. For the 21 patients with “small” tumors, the disease-free survival (DFS) rate is 90%. In this group two patients with clinical stage (CS) III disease have relapsed but both are alive after successful salvage treatment. The median follow-up time is 69.7+ months. For the 16 patients with larger tumor masses (>4 cm) the DFS rate is 87.5%. In this group one patient with CS II relapsed and died of Hodgkin's disease, and one with CS III relapsed after 37 months, but is now without evidence of disease, 61 months from diagnosis. The median follow-up time is 62+ months. Most of the children with Hodgkin's disease diagnosed before or during puberty can be cured with chemotherapy alone, and thus will not suffer from the damaging late effects of radiotherapy.

Ancillary